Difference between revisions of "FDG-PET Biomarker Ctte"
Line 24: | Line 24: | ||
Drafting: | Drafting: | ||
+ | *[[Media:QIBA FDG-PET Profile v0.7 23MAY2012doc.doc|QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v0.7)]] ''23MAY2012'' | ||
*[[Media:QIBA FDG-PET Profile v0 6 1 8 11MAY2012.doc|QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v0.6.1.8)]] ''11MAY2012'' | *[[Media:QIBA FDG-PET Profile v0 6 1 8 11MAY2012.doc|QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v0.6.1.8)]] ''11MAY2012'' | ||
*[[Media:QIBA FDG-PET Profile v0 5 9 08MAR2012.doc|QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v0.5.9)]] ''08Mar2012'' | *[[Media:QIBA FDG-PET Profile v0 5 9 08MAR2012.doc|QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v0.5.9)]] ''08Mar2012'' | ||
Line 34: | Line 35: | ||
* [[Media: Profile_FDG-PET_03122011.doc|Whole Body FDG-PET]] ''Word version of Profile applicable to multiple indications, 03-12-2011'' | * [[Media: Profile_FDG-PET_03122011.doc|Whole Body FDG-PET]] ''Word version of Profile applicable to multiple indications, 03-12-2011'' | ||
* [[Profile: FDG-PET Whole Body]] ''First version of Profile, 2009 (currently inactive)'' | * [[Profile: FDG-PET Whole Body]] ''First version of Profile, 2009 (currently inactive)'' | ||
− | |||
==Research Papers Analyzing FDG-PET Test-Retest Variability== | ==Research Papers Analyzing FDG-PET Test-Retest Variability== |
Revision as of 16:28, 24 May 2012
Quantitative FDG-PET Technical Committee Mission
- Mission; Foster adoption of ...
- pragmatic and cost effective standards for
- accurate and reproducible
- longitudinal
- quantitation of
- biologic parameters
- with clinical relevance
- and known sigma
Meetings / Call Summaries
UPICT Protocol Development
Profile Development
Drafting:
- QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v0.7) 23MAY2012
- QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v0.6.1.8) 11MAY2012
- QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v0.5.9) 08Mar2012
- QIBA Profile: FDG-PET as an Imaging Biomarker Predicting Response to Cancer Therapy for Oncologic Drug Development (v0.5.8) 03Feb2012
- FDG-PET/CT Profile: Status Update and Plan Presentation from 02.03.2012
- QIBA Profile: FDG-PET as an Imaging Biomarker Predicting Response to Cancer Therapy for Oncologic Drug Development (v0.5.7) 01-16-2012
- QIBA Profile: FDG-PET as an Imaging Biomarker Predicting Response to Cancer Therapy for Oncologic Drug Development (v0.5.6) 01-08-2012
- Whole Body FDG-PET Word version of Profile applicable to multiple indications, 04-19-2011
Archive:
- Whole Body FDG-PET Word version of Profile applicable to multiple indications, 03-12-2011
- Profile: FDG-PET Whole Body First version of Profile, 2009 (currently inactive)
Research Papers Analyzing FDG-PET Test-Retest Variability
- Hatt M, Cheze-Le Rest, C, Aboagye EO, et al. Reproducibility of 18F-FDG and 3'-Deoxy-3'-18F-Fluorothymidine PET Tumor Volume Measurements. The Journal of Nuclear Medicine2010; 51(9):1368-1376. [1]
- Kamibayashi T, Tsuchida T, Demura Y, et al. Reproducibility of Semi-quantitative Parameters in FDG-PET Using Two Different PET Scanners: Influence of Attenuation Correction Method and Examination Interval. Academy of Molecular Imaging 2008; 10:162-166.[2]
- Krak NC, Boellaard R, Hoekstra OS, et al. Effects of ROI Definition and Reconstruction Method on Quantitative Outcome and Applicability in a Response Monitoring Trial. European Journal of Nuclear Medicine and Molecular Imaging 2005; 32(3):294–301.[3]
- Minn H, Zasadny KR, Quint LE, Wahl RL. Lung Cancer: Reproducibility of Quantitative Measurements for Evaluating 2-[F-18]-Fluoro-2-deoxy-D-glucose Uptake at PET1. Radiology 1995; 196:167-173.[4]
- Nahmias C, Wahl LM. Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors. The Journal of Nuclear Medicine 2008; 49(11):1804-1808. [5]
- Nakamoto Y, Zasadny KR, Heikki M, Wahl RL. Reproducibility of Common Semi-quantitative Parameters for Evaluating Lung Cancer Glucose Metabolism with Positron Emission Tomography Using 2-Deoxy-2-[18F] Fluoro-D-Glucose. Molecular Imaging and Biology 2002; 4(2):171-178. [6]
- Velasquez, LM, Boellaard R, Kollia G, et al. Repeatability of 18F-FDG PET in a Multicenter Phase I Study of Patients with Advanced Gastrointestinal Malignancies. The Journal of Nuclear Medicine 2009;50:1646-1654. [7]
- Weber WA, Ziegler SI, Thodtmann R, et al. Reproducibility of Metabolic Measurements in Malignant Tumors Using FDG PET. The Journal of Nuclear Medicine 1999; 40(11):1771-1777. [8]
Working Documents and Reference Materials
- Lung Cancer: Reproducibility of Quantitative Measurements for Evaluating FDG-PET
- 02.17.2012 QIBA FDG-PET Data Warehouse Use Case and Requirements
- Agenda from 02.17.2012 FDG-PET Tech Committee Call
- Covariates Rationale
- Standardized Uptake Value (SUV)
- Quality Control Metrics
- ROI Definition
- Software Version Tracking
- Covariates Rationale SubCtte March 2009
- Digital Reference Objects SubCtte March 2009
- Quality Control Metrics SubCtte March 2009
- Region of Interest SubCtte March 2009
- Software Version Tracking SubCtte March 2009
The Netherlands Standardization Protocol for Quantitative FDG-PET in Multi-center Trials (English translation of Version 1)
Please keep the following in mind:
The development of this protocol was started about 2005 and approved more than 1 year ago in The Netherlands (NL). However, with gained insight, changes are scheduled to be incorporated in the next version by 2010. The following changes will be made (consider them being applied already or underway):
- Use of oral contrast is now excluded but will be allowed in the next version
- We are currently working on standards for CT as well, including GL for doing CT-QC (in cooperation with the radiologists/radiology societies in NL)
- There will be an upper limit for dosage
- We are working on traceable/calibrated and mutually linked sources for both PET and the dose calibrator and these will be used for absolute (rather than cross-) calibration (but in addition to the cross-calibration using FDG).
- Reconstruction settings given in the protocol are indicative and are likely not applicable for future scanners and software upgrades. Therefore reconstruction parameters should be set such that they provide results that meet the specifications given for the multi-center QC experiments. Same settings should then be applied to patient studies (see also comments under "execptions/special features” and comments made in the paper by Boellaard et al. EJNMMI 2008).
- Various other minor edits/typos/changes
The protocol is not a step-by-step description of the logistics for doing a PET/CT study. However, it has been set up in a somewhat chronological order and may thus be used to populate (copy-paste) such a step-by-step description. Additional work required ... FDG-PET/CT Technical Committee input is highly appreciated.
Submitted by Ronald Boellaard, PhD
Submitted by Richard L. Wahl, MD and Martin A. Lodge, PhD
Submitted by Eric S. Perlman, MD
Slide Presentations
- QIBA Informational Meeting (Dec 1st at RSNA 2008) - Slide Content Review
- QIBA Working Meeting (Dec 4th at RSNA 2008) - FDG-PET/CT Breakout Session Slide Deck
- Fused Images
- Media:FDG-PET11-29.ppt
- QIBA FDG-PET/CT Mission Statement - 2009.03.10
- QIBA Profiling Process-03.31.2009 (Andrew Buckler, MS)
- FDG-PET/CT Technical Committee summary 2009.05.20 Richard Frank
Round 1 of QIBA Funded Projects